Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
about
Natural killer cells in hepatitis C: Current progressImmune responses to HCV and other hepatitis virusesSTAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liverEmerging concepts in immunity to hepatitis C virus infection.Signal transducer and activator of transcription 4 in liver diseasesNatural killer cells in liver diseaseNatural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patientsHepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression.Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents.Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Immune control and failure in HCV infection--tipping the balance.Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients.Natural Killer Cells in Viral Hepatitis.CD100 up-regulation induced by interferon-α on B cells is related to hepatitis C virus infection.STING agonists induce an innate antiviral immune response against hepatitis B virus.PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis CIFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research.Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cellsSuccessful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.Natural killer and natural killer T cells in liver fibrosisImpaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.Changing partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections.Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity.The natural killer cell response to HCV infection.Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C.Therapeutic depletion of natural killer cells controls persistent infection.The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment.STAT4-associated natural killer cell tolerance following liver transplantation.Type I interferon regulation of natural killer cell function in primary and secondary infections.Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.Immune regulation in chronic hepatitis C virus infection.IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells.Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users.Interferon-Mediated Cytokine Induction Determines Sustained Virus Control in Chronic Hepatitis C Virus Infection.
P2860
Q26773264-4453E25A-FAF0-4C02-8E4B-4B28F06258F6Q26866955-4D3BB907-C96A-435C-B0DB-E34626D99B36Q27000742-C85B860C-FE15-4D50-B722-47F4E2BB1DF9Q27002588-D41ACB1B-F1A9-4D9A-BA8D-F189A740715FQ27016571-15E48CBF-AE9F-4046-865F-FE0F76A22B8EQ27025451-4A658301-1AD3-4F29-A7F9-F5CBEA584217Q31115968-ABCA5C0A-0408-4FBC-BDF3-78F163ED4E47Q33553433-DBFDCBF0-4473-4C49-8A24-9687C830B8F9Q33588171-502C5A25-EA99-48F9-91C9-DDC0050D8005Q33711206-F04B9A56-1EE7-42A4-897F-44828D7C2C28Q33745372-356DB407-1BB6-43CD-A6AA-3AFCF851683DQ34178628-796B44CE-423F-410C-9F5F-297B8F62F3CCQ34469926-5D246D6A-175D-4A65-87A3-7494C252313AQ34505690-0E51125D-2DD1-460E-B1CB-48B4FBD7BF4FQ34599645-98AD5992-3D81-4D92-B01F-231F12B4F7CAQ35105855-782802F0-3D1B-4E3F-986F-C6CBA14A544CQ35153981-F59F0832-5B09-4E0C-9A8F-8D24F90CA29FQ35675878-20CC4CEC-6234-4E60-918D-FFD55832AEF6Q35748913-19A6F8D0-057A-48B4-97C9-E53B2BE48A51Q35786326-5A4BE208-22E8-413F-8D11-CE15C47C1D78Q35911913-969D81DE-A0C7-4A63-98B8-EAC99A98EA6BQ36073739-2EC233C4-F4A7-4963-AB11-711A4ED0BE29Q36295405-36AC6B11-0150-46B3-B126-491EAB2EF6D1Q36553227-E4408617-F823-4219-86AA-236A86EF917CQ36606736-AF4CC23F-B569-4859-B982-8F8078B4F027Q36895423-391A03C7-5E2E-4E67-A5FC-E4B8376CE058Q37194029-22E06EED-7041-4675-8B90-AAF423572B74Q37279158-603F2578-B941-4779-BC7D-60DE46AB3484Q37294033-8E0EB48A-2766-40E9-964E-7F51EA7210ADQ37358617-F62ADB81-998B-4C49-B8F9-66B99292E219Q37547157-3E2CD157-FF30-44CE-AD31-7DCBF2BF54F7Q37599511-FC7084AC-8CC1-4DF9-AD8B-CB8A6FE536F2Q37617088-3754A96A-8C8C-44B4-841E-88C3F2949A15Q38132264-D00669B3-2835-4E64-B3BE-2A4B83B7CB0AQ38223279-BC386C20-593A-44C3-B72C-B41BAEBBE055Q38458110-61D592DB-BA8C-4409-92F3-E0DE02CA4DF5Q38902559-705382C1-DE7A-437B-A67D-64391575C26DQ39153508-D9874D0E-A9DB-4708-BB5E-895EEF291934Q40809341-707AB12F-F3C1-4E84-B75C-DD2D545AAC55Q40936303-BB485B6B-D0CB-4383-B6D4-DD5D9917FA17
P2860
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Early changes in interferon si ...... erapy of hepatitis C patients.
@ast
Early changes in interferon si ...... erapy of hepatitis C patients.
@en
type
label
Early changes in interferon si ...... erapy of hepatitis C patients.
@ast
Early changes in interferon si ...... erapy of hepatitis C patients.
@en
prefLabel
Early changes in interferon si ...... erapy of hepatitis C patients.
@ast
Early changes in interferon si ...... erapy of hepatitis C patients.
@en
P2093
P2860
P356
P1433
P1476
Early changes in interferon si ...... herapy of hepatitis C patients
@en
P2093
Aintzane Zabaleta Azpiroz
Barbara Rehermann
Birgit Edlich
Elisavet Serti
Jonathan Stoltzfus
Jordan J Feld
Mazen Noureddin
T Jake Liang
P2860
P356
10.1002/HEP.24628
P407
P577
2011-11-14T00:00:00Z